Amol Akhade: I-DXD shows promising activity in heavily pretreated Extensive stage SCLC

Amol Akhade shared on LinkedIn:

“I-DXD ( Ifinatamab Deruxtecan) shows promising activity in heavily pretreated Extensive stage SCLC. Impressive results from the IDeat-Lung01 phase 2 study reveal a 90.5% disease control rate with a median progression-free survival of 5.5 months and a median overall survival of 11.8 months for 12 mg per Kg dose

With patients having undergone 2 prior lines of therapy, and 76% receiving prior IO, these outcomes are significant. The Phase 3 trial, IDeat-lung 02, is currently ongoing, continuing the progress in this area.”

Read Further.
Source: Amol Akhade/LinkedIn

More posts featuring Amol Akhade on oncodaily.com

Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.